ArticleTranslational pediatrics2025
Successful treatment with decompressive laparotomy for abdominal compartment syndrome induced by asparaginase-associated pancreatitis in a pediatric patient with acute lymphoblastic leukemia: a case report.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asparaginase (ASP) has significantly improved the complete remission rate and long-term event-free survival in children with acute lymphoblastic leukemia (ALL). Asparaginase-associated pancreatitis (AAP) is a potentially toxic side effect of ASP, which may even lead to fatal abdominal compartment syndrome (ACS) in extreme cases. Currently, there is no consensus on the indications for decompressive laparotomy (DL), including when to initiate it, what criteria to use for decision-making, or how to perform the procedure. Moreover, available research data remain limited. Case Description: We present a case of a 2-year-old boy with ALL who developed ACS, a fatal complication of severe acute pancreatitis (SAP) following treatment with pegaspargase (PEG-ASP). Massive transfusion stabilized his hemodynamics and intraluminal contents were evacuated, yet his symptoms progressed. Consequently, the patient underwent DL and continuous venovenous hemodiafiltration (CVVHDF) with ultrafiltration. Postoperative complications including enteroatmospheric fistulas and abdominal abscesses were gradually corrected by negative-pressure wound therapy (NPWT). The boy was discharged from the intensive care unit (ICU) on the 93rd day after hospital admission. During follow-up, the child's abdominal symptoms gradually improved, and bridging therapy with blinatumomab was administered. Conclusions: In this case, a pediatric ALL patient developed life-threatening complications following PEG-ASP administration, which were ultimately successfully managed through multidisciplinary intervention. When pediatric hematology-oncology patients develop ACS, clinicians should carefully evaluate the oncological context and thoroughly assess the risks of surgical versus conservative management for this potentially fatal condition. Optimal timing of surgical intervention combined with advanced perioperative care is critical for achieving favorable outcomes. We strongly recommend conducting high-quality clinical research to establish evidence-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.